Adam P. Dicker, MD, PhD
Room G-301, Bodine Center
Philadelphia, PA 19107
(215) 503-0013 fax
Most Recent Peer-reviewed Publications
- High dose rate brachytherapy boost for prostate cancer: A systematic review
- Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets
- Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
- A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
- Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?
Cornell University Medical College, New York, NY (MD) - 1992
Memorial Sloan-Kettering Cancer Center, New York, NY
American Cancer Society Clinical Oncology Fellowship, Memorial Sloan-Kettering Cancer Center, Department of Radiation Oncology, New York, NY
American Board of Radiology (Radiation Oncology): 1997, Recertified in 2000
Professor, Department of Pharmacology and Experimental Therapeutics (2010)
Jefferson Graduate School of Biomedical Sciences, Faculty Appointment in the Molecular Pharmacology and Structural Biology PhD Program (2011)
Research and Clinical Interest
I am an international authority in Radiation Oncology, drug development and the treatment of prostate cancer and brain tumors.
I co-lead the Radiation Research and Translational Biology Program at the Kimmel Cancer Center at Thomas Jefferson University. In addition, I serve as the Director of the Christine Baxter Research Laboratory for Experimental Cancer Therapies at Jefferson Medical College. I have been a principal investigator in a significant number of “first in human” developmental therapeutic trials involving novel signal transduction agents and radiation therapy. My colleagues and I have developed new approaches to radiation therapy for the treatment of cancer, and have successfully applied their findings from the laboratory to the clinical setting.
I serve as the Chair of the Translational Research Program in the Radiation Therapy Oncology Group (RTOG), a National Cancer Institute-sponsored cooperative group. I formerly served as Chair of the Radiation and Cancer Biology Committee of the American Society of Therapeutic Radiation Oncology. I represent the RTOG on the National Cancer Institute’s Investigational Drug Steering Committee of Cancer Treatment Evaluation Program and also serve as a consultant on cancer to the European Commission, the National Cancer Institute of Canada and the Italian Association of Cancer Research. My reputation in research and clinical practice ranks him among Philadelphia Magazine’s “Top Docs” in Radiation Oncology and in Castle-Connolly America’s Top Doctors for Cancer. I published extensively and have more than 150 peer-reviewed journal articles and chapters.
I also serve on the editorial boards of Clinical Cancer Research, Cancer Biology, BMC Cancer and Radiation Oncology, and also provides reviews for eight additional journals as well.